Adlai Nortye (NASDAQ:ANL – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports.
Adlai Nortye Stock Up 1.1 %
Shares of ANL opened at $3.65 on Thursday. The firm’s fifty day simple moving average is $9.81 and its two-hundred day simple moving average is $9.25. Adlai Nortye has a 12 month low of $3.21 and a 12 month high of $19.30.
Hedge Funds Weigh In On Adlai Nortye
An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its holdings in Adlai Nortye Ltd. (NASDAQ:ANL – Free Report) by 128.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 at the end of the most recent quarter. Institutional investors and hedge funds own 35.21% of the company’s stock.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
- Five stocks we like better than Adlai Nortye
- Business Services Stocks Investing
- Sarepta Therapeutics Stock Soars on FDA Approval
- What is MarketRankā¢? How to Use it
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- Insider Trades May Not Tell You What You Think
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.